Document Detail

Tolerability and compliance with risedronate in clinical practice.
MedLine Citation:
PMID:  12730745     Owner:  NLM     Status:  MEDLINE    
The purpose of this study was to determine compliance with dosing instructions, and the prevalence of possible adverse events, when risedronate is used in clinical practice. 219 patients were studied. We found that despite counseling one in four patients were non-compliant with dosing instructions. Those patients who did not stay upright after taking risedronate were more likely to have an adverse event and to discontinue the drug. Adverse events were experienced by 38% of patients, the commonest being gastrointestinal. Upper GI adverse events occurred in 21% of patients. A previous history of upper GI symptoms applied to 44% of patients and significantly more of them experienced upper GI adverse events than those with no history of GI problems. Forty two (19%) of patients taking risedronate stopped therapy due to adverse events, but only ten of these patients had contacted the Osteoporosis Unit about these symptoms. Approximately one third of the patients who experienced adverse events in this study had attempted a rechallenge with the drug. This was worthwhile, however, as in almost 50% of these patients their symptoms settled and they continued with therapy. This study has highlighted the importance of following up patients on long-term osteoporosis medication to ensure optimal compliance. The use of specialized osteoporosis nurses in clinics or primary care to follow up patients needs to be addressed.
B Hamilton; K McCoy; H Taggart
Related Documents :
21958235 - Suicides during 7 years among a catchment area cohort of patients with psychoses.
3944855 - Supine flexible cystoscopy.
3893075 - Patient compliance.
21870385 - Time of psychiatric patient assaults: twenty-year analysis of the assaulted staff actio...
20856935 - Demographic and clinical features of dengue fever in pakistan from 2003-2007: a retrosp...
8910095 - Serotoninergic drug-induced weight loss in carbohydrate craving obese patients.
Publication Detail:
Type:  Journal Article     Date:  2003-04-10
Journal Detail:
Title:  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA     Volume:  14     ISSN:  0937-941X     ISO Abbreviation:  Osteoporos Int     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-05-27     Completed Date:  2006-10-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100105     Medline TA:  Osteoporos Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  259-62     Citation Subset:  IM    
Department of Healthcare of the Elderly, Belfast City Hospital, Belfast, Northern Ireland, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Bone Density Conservation Agents / adverse effects,  therapeutic use*
Etidronic Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Gastrointestinal Diseases / chemically induced
Middle Aged
Osteoporosis / drug therapy*,  psychology
Osteoporosis, Postmenopausal / drug therapy,  psychology
Patient Compliance / psychology*
Patient Dropouts
Reg. No./Substance:
0/Bone Density Conservation Agents; 105462-24-6/risedronic acid; 2809-21-4/Etidronic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effect of DXA scanning on clinical decision making by general practitioners: a randomized, prosp...
Next Document:  A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by ...